Q-omics provides the consensus-scored KBTBD11-OT1 profile across patient tissues and cancer cell-line models. KBTBD11-OT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, KBTBD11-OT1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, KBTBD11-OT1 RNA expression shows 14,855 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KICH, and UVM as cancer lineages where KBTBD11-OT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD11-OT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD11-OT1 survival associations across molecular data types. KBTBD11-OT1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD11-OT1 RNA expression–survival associations across cancer types. High KBTBD11-OT1 expression shows unfavorable associations in UCEC, LUSC, GBM and LUAD, but favorable associations in READ and LIHC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify UCEC as the clearest survival context for KBTBD11-OT1 RNA expression.
This table summarizes KBTBD11-OT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for KBTBD11-OT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD11-OT1 shows lower tumor expression in KICH, COAD, LIHC, READ and THCA and higher tumor expression in KIRC. The KICH box plot shows higher KBTBD11-OT1 RNA expression in normal versus tumor tissue (log2 FC = −1.688, t-test p < 0.001).
This table shows molecular features associated with KBTBD11-OT1 in patient tissues and cancer cell lines. In patient samples, KBTBD11-OT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
